NASDAQ:HSCS HeartSciences Q1 2027 Earnings Results & Report $3.18 +0.14 (+4.61%) Closing price 10/9/2026 04:00 PM EasternExtended Trading$3.16 -0.02 (-0.66%) As of 10/9/2026 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. HeartSciences missed analyst expectations on both earnings and revenue in its Q1 2027 results, released September 14, 2026. The company reported EPS of -$0.86 versus the -$0.72 consensus estimate, while revenue of $0.00 million fell short of the $0.10 million estimate by $0.10 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2027Report DateSeptember 14, 2026TimeBefore Market OpensConference Call7:00 AM ET HeartSciences EPS ResultsActual EPS-$0.86Consensus EPS -$0.72Beat/MissMissed by -$0.14One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersHeartSciences Revenue ResultsActual Revenue$0.00 millionExpected Revenue$0.10 millionBeat/MissMissed by -$97.90 thousandYoY Revenue GrowthN/AUpcoming EarningsHeartSciences' Q2 2027 earnings is estimated for Monday, December 21, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, December 16, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) HeartSciences Q1 2027 Earnings FAQ Did HeartSciences beat earnings estimates for Q1 2027? HeartSciences (NASDAQ:HSCS) reported earnings of -$0.86 per share for Q1 2027, missing the consensus estimate of -$0.72. The report was announced on Monday, September 14, 2026. What was HeartSciences' revenue for Q1 2027? HeartSciences reported revenue of $0.00 million for Q1 2027, against a consensus estimate of $0.10 million. When is HeartSciences' next earnings date? HeartSciences' next earnings date is estimated for Monday, December 21, 2026. MarketBeat tracks confirmed and estimated earnings dates for HeartSciences on the company's earnings history page. HeartSciences Earnings HeadlinesHeartSciences Wins FDA Clearance For MyoVista WavECG; Fortitude Lines Up $100 Mln Miner DealOctober 6, 2026 | rttnews.comHeartSciences' MyoVista WavECG Device Gets FDA 510(k) ClearanceOctober 6, 2026 | rttnews.comWhat’s Elon building now?New drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and built in a matter of weeks. James Altucher says the site could go live as soon as October 21 and has put together a free presentation explaining what is happening inside and why the timing matters.October 10 at 1:00 AM | Paradigm Press (Ad)HeartSciences Receives FDA 510(k) Clearance for its MyoVista® wavECGTM DeviceOctober 6, 2026 | globenewswire.comFortitude Secures Priority Supply Allocation for BITMAIN’s Next-Generation Zcash Mining Equipment, Announces $100 Million Non-Binding Purchase Commitment, and Additional ...October 5, 2026 | marketscreener.comMHeartSciences Extends Loan Terms Amid Pending MergerOctober 2, 2026 | tipranks.comSee More HeartSciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like HeartSciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HeartSciences and other key companies, straight to your email. Email Address About HeartSciencesHeartSciences (NASDAQ:HSCS), Inc. (NASDAQ: HSCS) is a medical technology company focused on improving the detection and diagnosis of heart disease. The company develops electrocardiography (ECG) technologies designed to provide clinicians with additional information about cardiac function using a familiar, noninvasive test. Its principal product is the MyoVista waveform ECG, which uses proprietary time-frequency analysis to evaluate electrical signals from the heart. The technology is intended to help identify abnormalities that may be associated with impaired cardiac relaxation, including diastolic dysfunction, which can be difficult to detect with conventional ECG methods. HeartSciences markets its products to healthcare providers and cardiovascular-care organizations. The company’s technology has received regulatory clearance for use in the United States and has also been made available in international markets, including Europe. HeartSciences is headquartered in Southlake, Texas.View HeartSciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 10/05 - 10/09Delta Air Lines Faces a Fuel Crisis—But There's a Silver LiningPalantir’s Rally Puts Wall Street in Catch-Up Mode Ahead of November EarningsApplied Digital’s Hidden Moat Could Unlock Massive UpsideLevi's Stock Dip Reveals Value Opportunity Despite Q3 HeadwindsTilray Finds a Path to Growth Without Waiting on U.S. Cannabis ReformPepsiCo Stock Looks Poised to Bottom With High Yield, Deep Value Upcoming Earnings Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
